Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 350.91% | 244.60% | 161.81% | 46.47% | -14.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 350.91% | 244.60% | 161.81% | 46.47% | -14.02% |
| Cost of Revenue | 122.22% | 124.35% | 239.77% | 286.28% | 241.33% |
| Gross Profit | 455.65% | 295.44% | 140.32% | 25.56% | -35.96% |
| SG&A Expenses | 41.50% | 35.56% | 66.06% | 70.75% | 56.51% |
| Depreciation & Amortization | -38.06% | -4.25% | 66.20% | 174.87% | 707.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.08% | 1.91% | 24.31% | 32.36% | 43.53% |
| Operating Income | 95.13% | 66.61% | 19.24% | -25.53% | -75.40% |
| Income Before Tax | 196.16% | 159.83% | 132.11% | -52.50% | -95.75% |
| Income Tax Expenses | -77.56% | -- | 10,494.35% | 50,272.73% | -- |
| Earnings from Continuing Operations | 178.88% | 139.40% | 103.96% | -86.01% | -129.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 178.88% | 139.40% | 103.96% | -86.01% | -129.13% |
| EBIT | 95.13% | 66.61% | 19.24% | -25.53% | -75.40% |
| EBITDA | 99.78% | 70.91% | 23.97% | -19.41% | -65.88% |
| EPS Basic | 163.02% | 125.52% | 90.87% | -47.44% | -75.89% |
| Normalized Basic EPS | 96.77% | 68.08% | 20.39% | -22.36% | -51.20% |
| EPS Diluted | 160.76% | 123.90% | 88.98% | -47.79% | -76.24% |
| Normalized Diluted EPS | 96.64% | 68.38% | 20.77% | -22.36% | -51.20% |
| Average Basic Shares Outstanding | 19.61% | 28.26% | 33.76% | 32.29% | 30.43% |
| Average Diluted Shares Outstanding | 21.69% | 29.17% | 34.74% | 32.29% | 30.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |